USING REAL-WORLD PATIENT SCENARIOS AND SIMULATIONS TO OVERCOME BARRIERS TO APPROPRIATE USE OF ORAL ANTICOAGULANTS-UNPROVOKED VTE
June 27, 2019
June 27, 2020
Scroll to the Bottom of this Information to Begin this Course
This activity is joinly provided by AKH Inc., Advancing Knowledge in Healthcare and ASiM CE, LLC..
Supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance.
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
- Nurses — 0.5 contact hours.
- Pharmacists — 0.5 contact hours.
All other health care professionals completing this course will be issued a statement of participation.
Physicians, vascular medicine and surgery, pulmonology, hematology, emergency medicine specialists, PCPs, RNs, and PharmDs
For longer-term anticoagulation treatment, choosing among the different options frequently depends upon clinician experience and drug availability, risks of bleeding, patient comorbidities, patient preferences, cost, and convenience. Both direct oral anticoagulants (DOACs) and warfarin have advantages and disadvantages. In the setting of an unprovoked venous thromboembolism (VTE), many patients will require long-term secondary prevention. As with many preventive treatments for any chronic disease, adherence is often suboptimal, but the efficacy and safety of the OACs depends on adherence. Using a case-based format, this activity will review risk stratification, treatment options, and duration of therapy for patients with an unprovoked VTE, as well as common barriers to adherence with OAC therapy and strategies to engage patients to overcome those barriers.
The goal of this program is to provide both specialists (in vascular medicine and surgery, pulmonology, and hematology), primary providers (community-based cardiologists, primary care physicians, pharmacists, nurse practitioners, physician assistants, and nurses), and emergency department providers with the evidence-based knowledge and skills to treat patients with unprovoked VTE with the appropriate duration and choice of OAC. This activity will also address patient barriers to adherence to long-term anticoagulant therapy for secondary prevention.
Upon completion of this activity, participants should be able to:
- IMPLEMENT risk stratification of patients to determine who would benefit from extended oral anticoagulant therapy following an unprovoked VTE.
- IDENTIFY the risk factors for recurrence in patients with unprovoked VTE.
- REVIEW the evidence for the different types of OAC therapy and their duration following an unprovoked VTE.
- DEVELOP strategies to engage patients to overcome barriers to optimal adherence to OACs.
Jeffrey Weitz, MD, FRCP(C), FACP (Course Director)
Professor of Medicine and Biochemistry, McMaster University
Heart and Stroke Foundation/JF Mustard Chair in Cardiovascular Research
Canada Research Chair (Tier 1) in Thrombosis
Executive Director, Thrombosis and Atherosclerosis Research Institute
Hamilton, Ontario, Canada
He is Board certified in internal medicine, hematology, and medical oncology and focuses his clinical practice on patients with thrombotic disorders. His research spans the spectrum from basic studies in the biochemistry of blood coagulation and fibrinolysis, to animal models of thrombosis, as well as clinical trials of antithrombotic therapy.
His extensive work has been published in over 500 journals including the Journal of Clinical Investigation, the Journal of Biological Chemistry, Biochemistry, Circulation, Blood, the Annals of Internal Medicine, the New England Journal of Medicine, and Lancet, as well as 60 book chapters. Dr Weitz is also a fellow of the American Heart Association, the Royal Society of Canada, and the Canadian Academy of Health Sciences.
Dr Weitz is involved in clinical trials that examine optimal methods for the prevention, diagnosis, and treatment of clotting disorders, and is an active participant in the education of medical students, residents, and postdoctoral fellows. Dr Weitz also coordinates a graduate course in medical sciences, and his laboratory is a fertile training ground for graduate students and postdoctoral fellows in the medical sciences and bioengineering.
Marc Carrier, MD, MSc, FRCPC
Professor, Department of Medicine
University of Ottawa
Senior Scientist, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Dr Carrier’s clinical research is focused on VTE disease and cancer, specifically cancer screening, prevention, and management. He is currently the Principal Investigator of 4 peer-reviewed clinical trials (Heart and Stroke Foundation  and Canadian Institutes of Health Research ) and numerous industry-sponsored trials. He has published important systematic reviews and has had multiple international speaking invitations to speak on the topics of cancer and thrombosis.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc., Advancing Knowledge in Healthcare and ASiM CE, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is awarded 0.5 Contact Hour.
AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge‐based activity for 0.5 contact hour (0.05 CEU). UAN: 0077-9999-19-012-H04-P. Initial Release date: June 19, 2019.
Activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and ASiM CE, LLC.
Criteria for Success
Statements of credit will be awarded based on the participant reviewing each presentation, scoring a 70% on the post test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participant in this activity. If you have questions about this CE activity, please contact AKH Inc. at firstname.lastname@example.org.
Dr Weitz as disclosed the following relevant financial relationships:
Consultant - Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Ionis, Janssen, Merck, Novartis, Pfizer, Portola.
Dr Carrier as disclosed the following relevant financial relationships:
Advisory Board/Consultative Meetings - Aspen, Bayer, Bristol-Myers Squibb, LEO Pharma, Pfizer, Sanofi, Servier
Contracted Research - Bayer, Bristol-Myers Squibb, LEO Pharma, Octapharma
Speakers Bureau - Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, LEO Pharma, Pfizer, Sanofi, Servier
Trish Brignoni, Director of Operations, discloses no financial relationships with pharmaceutical or medical product manufacturers.
Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner, discloses no financial relationships with pharmaceutical or medical product manufacturers.
ASiM CE, LLC and AKH Inc, planners and reviewers have disclosed no financial relationships with pharmaceutical or medical product manufacturers.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.
Continuing Medical Education and Continuing Education
When you register for a Continuing Medical Education (CME) or a Continuing Education (CE) activity through one of our Web sites, we collect certain personally identifiable information from you such as your name, email address and mailing address. If you are a pharmacist and wish to receive CE credit, you are also required to provide your NAPB # and month and day of birth. For more information about NABP and CPE Monitor click here. In addition to personally identifiable information, we collect aggregated non-personally identifiable information about the activities undertaken by our users. We use the information that we collect through CME/CE activities in several ways:
- We work with several accredited companies who are accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. As a joint-provider, we are required periodically to submit aggregated data about CME participants and the CME activities we certify. We also provide personally identifiable information to other accredited CME/CE providers who certify CME/CE activities posted on our Web sites, as required by the ACCME and other accrediting bodies. These reports may include personally identifiable information about you and credits issued to you, for the purpose of maintaining records that you can request from the accredited provider for up to six (6) years;
- Commercial supporters of CME/CE activities on our Web site will receive only aggregated data about CME/CE activities that are relevant to their interests and/or the courses they support;
- Our Editorial and Customer Support Staff will have internal access to files containing personally identifiable information, including evaluation forms and aggregated CME /CE participant information. These files can be accessed in order to respond to your questions or comments. Our staff may also use personally identifiable information, including registration information and evaluation data, in assessing educational needs and planning marketing activities.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
For video playback, install the latest version of Flash or Quicktime.